{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": [
        "ECOG Performance Status of III or IV",
        "Life expectancy of less than 6 months",
        "Active bleeding or a high risk of bleeding that contraindicates anticoagulant treatment, including active clinically significant bleeding",
        "Lesion or condition considered a significant risk factor for major bleeding (e.g., current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms, major intraspinal or intracerebral vascular abnormalities)",
        "Recent (within the last month) brain, spinal, or ophthalmic surgery",
        "Bacterial endocarditis",
        "Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg despite treatment)",
        "Hypersensitivity to the study drugs or their excipients",
        "Any condition that, in the investigator\u2019s judgment, would place the subject at increased risk of harm",
        "Women of childbearing potential not practicing a medically accepted, highly effective method of contraception during the trial and for one month beyond",
        "Pregnancy or breastfeeding",
        "Patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome",
        "Patients with prosthetic heart valves",
        "Acute hepatitis, chronic active hepatitis, liver cirrhosis, or an alanine aminotransferase level \u22653 times the upper limit of normal and/or a bilirubin level \u22652 times the upper limit of normal",
        "Hepatic disease associated with coagulopathy and clinically relevant bleeding risk",
        "Administration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization",
        "Receipt of 3 or more doses of a vitamin K antagonist before randomization",
        "Use of thrombectomy, vena cava filter insertion, or thrombolysis to manage the index VTE episode",
        "An indication for anticoagulant treatment for a condition other than the index VTE",
        "Concomitant treatment with any other anticoagulant agent (e.g., UFH, LMWHs, fondaparinux, oral anticoagulants) except under specific circumstances of switching anticoagulant therapy",
        "Concomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein",
        "Concomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor), aspirin over 165 mg daily, or dual antiplatelet therapy",
        "Participation in another pharmacotherapeutic program with an experimental therapy known to affect the coagulation system",
        "Creatinine clearance < 30 ml/min based on the Cockcroft-Gault equation (Apixaban not recommended in patients with creatinine clearance < 15 mL/min, or in patients undergoing dialysis)",
        "Hemoglobin level lower than 8 g/dL (5.0 mmol/L) or a platelet count <75x10\u2079/L",
        "History of heparin-induced thrombocytopenia",
        "Age less than 18 years"
    ]
}